Abstract
We report 12 Danish myelofibrosis patients who have been treated successfully with ruxolitinib despite having low platelet counts (< 50 × 109/L) during their treatment-course. The majority of the patients experienced marked clinical improvement. Serious side effects were only recorded in a single patient. It is concluded that JAK-inhibition with ruxolitinib is manageable in patients with low platelet counts and should be considered in symptomatic patients who otherwise might not be candidates for treatment.
Potential conflict of interest
Disclosure forms provided by the authors are available with the full text of this article at www.informaheathcare.com/lal.
Supplementary material available online
Supplementary Figures 1–12 to be found online http://www.tandfonline.com/doi/suppl/10.3109/10428194.2015.1046867